Binimetinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 435 publications
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Journal: Future oncology (London, England)
Published: March 31, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 30, 2026
A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 24, 2026
Repurposing Ilaprazole as a PP5 TPR Domain Binder with Modulatory Effects on MAPK Signaling.
Journal: ACS medicinal chemistry letters
Published: February 02, 2026
Remission of metastatic duodenal cancer after treatment with BRAF inhibitor
Journal: Ugeskrift for laeger
Published: January 30, 2026
Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.
Journal: The oncologist
Published: January 20, 2026
From empirical caution to precision resumption: model-informed management of a binimetinib overdose in a frail elderly patient.
Journal: European journal of clinical pharmacology
Published: December 15, 2025
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 09, 2025
Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?
Journal: Expert opinion on investigational drugs
Published: December 05, 2025
Turning the Tables: How Encorafenib and Binimetinib are Reshaping NSCLC Treatment.
Journal: Cancer investigation
Published: December 04, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.
Journal: Research square
Published: November 24, 2025
Last Updated: 04/28/2026